Gilead Sciences, Inc.
INHIBITORS OF PEPTIDYLARGININE DEIMINASES
Last updated:
Abstract:
The present disclosure relates to novel compounds for use in therapeutic treatement of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.
Status:
Application
Type:
Utility
Filling date:
21 Dec 2021
Issue date:
21 Jul 2022